Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coenzyme Q10 for Osimertinib-Induced Cardiac Toxicity in NSCLC
ChiCTR2600117424Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of coenzyme q10 in Cardiotoxicity, drug-induced cardiomyopathy, heart failure (HF) and 1 more (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Change in NT-proBNP from baseline in ARB vs ARB + coenzyme Q10 groups. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
coenzyme q10
03
Conditions
Cardiotoxicitydrug-induced cardiomyopathyheart failure (HF)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600117424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117424.